Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis - PubMed (original) (raw)
Review
. 2018 Jan;20(1):113-120.
doi: 10.1111/dom.13047. Epub 2017 Aug 10.
Affiliations
- PMID: 28656707
- DOI: 10.1111/dom.13047
Review
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
Zhiying Wang et al. Diabetes Obes Metab. 2018 Jan.
Abstract
Aims: To compare the efficacy and safety of dipeptidyl peptidase-4 inhibitors (DPP-4is) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) as monotherapy or add-on to metformin (Met) in patients with type 2 diabetes mellitus (T2DM).
Materials and methods: PubMed, Embase and ClinicalTrials.gov sites were systematically searched for randomized controlled trials to assess the efficacy and safety of DPP-4is and SGLT-2is in patients with T2DM. Risk ratio (RR) and weighted mean difference (WMD) were used to evaluate outcomes.
Results: In the analysis of 25 randomized trials, which involved 14 619 patients, SGLT-2is were associated with a significantly stronger reduction in haemoglobin A1c (HbA1c) (WMD 0.13%, 95% credible interval [CI], 0.04%-0.22%, P = .005) and fasting plasma glucose (FPG) (WMD 0.80 mmol/L, 95% CI, 0.58-1.01 mmol/L, P < .00001) than were DPP-4is. However, no significant difference between the 2 drug categories was found in the risk of hypoglycaemic events (RR, 0.99; 95% CI, 0.78-1.26, P = .92). SGLT-2is plus Met was associated with a more significant decrease in FPG (WMD 0.71 mmol/L, 95% CI, 0.43-1.00 mmol/L, P < .00001) than was DPP-4is plus Met. However, no differences were found in the reduction of HbA1c (WMD 0.11%, 95% CI, -0.03%-0.25%, P = .12) or the risk of hypoglycaemic events (RR, 1.02; 95% CI, 0.80-1.31, P = .86).
Conclusions: This review revealed that, compared to DPP-4is, SGLT-2is significantly reduced HbA1c, FPG and body weight without increasing the risk of hypoglycaemia in diabetes treatment.
Keywords: dipeptidyl peptidase-4 inhibitors; sodium-glucose cotransporter-2 inhibitors; type 2 diabetes mellitus.
© 2017 John Wiley & Sons Ltd.
Similar articles
- Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.
Jia S, Wang Z, Han R, Zhang Z, Li Y, Qin X, Zhao M, Xiang R, Yang J. Jia S, et al. Acta Diabetol. 2021 Jan;58(1):5-18. doi: 10.1007/s00592-020-01542-4. Epub 2020 Jun 8. Acta Diabetol. 2021. PMID: 32514989 - Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Watanabe Y, Gouda M, Iijima H. Kadowaki T, et al. Diabetes Obes Metab. 2018 Jan;20(1):77-84. doi: 10.1111/dom.13038. Epub 2017 Jul 31. Diabetes Obes Metab. 2018. PMID: 28608617 Free PMC article. - Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review.
Chai S, Niu Y, Liu F, Wu S, Yang Z, Sun F. Chai S, et al. J Diabetes Res. 2024 Jul 20;2024:8145388. doi: 10.1155/2024/8145388. eCollection 2024. J Diabetes Res. 2024. PMID: 39072050 Free PMC article. Review.
Cited by
- Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease.
Rastogi A, Januzzi JL Jr. Rastogi A, et al. J Clin Med. 2023 Apr 12;12(8):2824. doi: 10.3390/jcm12082824. J Clin Med. 2023. PMID: 37109162 Free PMC article. Review. - Estimation of marginal structural models under irregular visits and unmeasured confounder: calibrated inverse probability weights.
Kalia S, Saarela O, Escobar M, Moineddin R, Greiver M. Kalia S, et al. BMC Med Res Methodol. 2023 Jan 7;23(1):4. doi: 10.1186/s12874-022-01831-2. BMC Med Res Methodol. 2023. PMID: 36611135 Free PMC article. - Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors.
Singh AK, Singh R. Singh AK, et al. World J Diabetes. 2022 Jun 15;13(6):466-470. doi: 10.4239/wjd.v13.i6.466. World J Diabetes. 2022. PMID: 35800411 Free PMC article. - Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis.
Oh S, Purja S, Shin H, Kim M, Kim E. Oh S, et al. Diab Vasc Dis Res. 2022 May-Jun;19(3):14791641221106866. doi: 10.1177/14791641221106866. Diab Vasc Dis Res. 2022. PMID: 35686694 Free PMC article. - Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi-ethnic cohort study.
Goh LGH, Sun J, Ong BSK, Khoo D, Sum CF, Ng K. Goh LGH, et al. J Diabetes Metab Disord. 2022 Mar 3;21(1):521-555. doi: 10.1007/s40200-022-01004-4. eCollection 2022 Jun. J Diabetes Metab Disord. 2022. PMID: 35673518 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous